Ascensia Study Shows BGMS Selection Impact On Glycemic Control With Diabetes Management App

MADRID-At the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) 2020, Ascensia presented data from a study that assessed the performance of blood glucose monitoring systems (BGMSs) when used with mobile applications (apps) for diabetes management1. At the event, data from Ascensia’s first ever oral presentation highlighted the challenges of hypoglycemia management using apps and demonstrated that not all BGMSs using apps are capable of detecting hypoglycemia with a high probability, which has the potential to make them less effective in supporting glycemic control.

Apps for type 1 and type 2 diabetes management often rely on data from glucose monitoring devices, such as BGMSs. These apps are designed to provide support that can help to reduce the occurrence of hypoglycemia and enable more effective glycemic control. Therefore, the performance of these apps in hypoglycemia management is dependent on the quality and accuracy of the data from the BGMSs, particularly in the low blood glucose range (LBGR: ≤70 mg/dl).

The Ascensia sponsored study presented at ATTD used a statistical model applied to real BGMS data to calculate the probability of achieving ±15% of a reference blood glucose (BG) value of 50 mg/dl for a variety of available BGMSs that can link to apps for diabetes management1. The BGMSs included were CONTOUR®NEXT ONE (CNO), Accu-Chek Aviva Connect, FreeStyle Freedom Lite, GlucoMen Areo, and OneTouch Verio.

The study demonstrated that not all systems were capable of detecting hypoglycemia with a high probability. Based on this analysis in the LBGR, the probability of achieving ±15% of the reference BG value of 50 mg/dl for CNO was above 95%, whereas it was below 95% for some of the other BGMSs studied. Specifically, CNO’s predicted BG value was 50.74mg/dL, with a 95% confidence interval of ±3.25 mg/dL. This analysis shows that BGMS selection is critical in assessing the effectiveness of apps for glycemic control and hypoglycemia detection.

These results follow two recent studies that demonstrate the accuracy of products in the CONTOUR® portfolio in the LBGR, which are also being presented as posters at ATTD 20202,3. These two studies also used data from clinical trials applied to a linear regression model to calculate the likelihood of accurate BGMS performance in the LBGR. These assessments showed that the CNO, CONTOUR®PLUS (CP) and CONTOUR®PLUS ONE (CPO) BGMSs maintained high levels of accuracy in the LGBR, which is important for safe and effective diabetes management. The probability of having results within ±15% of the reference BG values was >95% for all three systems, and was in contrast to other systems included in these studies.

Together, the results of these studies highlight the importance of selecting a highly accurate BGMS in order to enable effective diabetes management through an app and demonstrate the high levels of accuracy of the three BGMSs from the CONTOUR® range in the LBGR.

First-of-its-kind data in Ascensia’s first ever oral presentation at ATTD, highlights the importance of meter selection for diabetes management apps by assessing accuracy at low blood glucose ranges. As healthcare sector evolves and merges with latest trend of digitization, fitness and healthcare apps have taken over the diagnostics part in the overall the medical examination.

On-demand fitness and health app is driving the global economy; Panacea Infotech can help you in meeting the pace of innovation and growth in on-demand solutions. We are pioneer app development company with proven expertise.